Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 411

1.

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.

Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, Brown TT, Rockstroh JK, Wei X, Carter CC, Zhong L, Brainard DM, Melbourne K, Das M, Stellbrink HJ, Post FA, Waters L, Koethe JR.

Clin Infect Dis. 2019 Oct 14. pii: ciz999. doi: 10.1093/cid/ciz999. [Epub ahead of print]

PMID:
31606734
2.

Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: Current incidence rates compared with rates during the interferon era.

Ingiliz P, Wehmeyer MH, Boesecke C, Schulze Zur Wiesch J, Schewe K, Lutz T, Baumgarten A, Simon KG, Hueppe D, Rockstroh JK, Mauss S, Christensen S; NEAT study group; GECCO study group.

Clin Infect Dis. 2019 Sep 28. pii: ciz949. doi: 10.1093/cid/ciz949. [Epub ahead of print]

PMID:
31562816
3.

Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment.

Mocroft A, Lundgren J, Gerstoft J, Rasmussen LD, Bhagani S, Aho I, Pradier C, Bogner JR, Mussini C, Uberti Foppa C, Maltez F, Laguno M, Wandeler G, Falconer K, Trofimova T, Borodulina E, Jevtovic D, Bakowska E, Kase K, Kyselyova G, Haubrich R, Rockstroh JK, Peters L; EuroSIDA Study .

Clin Infect Dis. 2019 Jul 2. pii: ciz601. doi: 10.1093/cid/ciz601. [Epub ahead of print]

PMID:
31504296
4.

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA).

Dold L, Schwarze-Zander C, Boesecke C, Mohr R, Langhans B, Wasmuth JC, Strassburg CP, Rockstroh JK, Spengler U.

Sci Rep. 2019 Aug 29;9(1):12502. doi: 10.1038/s41598-019-48756-3.

5.

Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study - 2012 - 2015.

Raben D, Sullivan AK, Mocroft A, Kutsyna G, Hadžiosmanović V, Vassilenko A, Chkhartisvili N, Mitsura V, Pedersen C, Anderson J, Begovac J, Bak Dragsted U, Bertisch B, Grzeszczuk A, Minton J, Necsoi VC, Kitchen M, Ajana F, Sokhan A, Comi L, Farazmand P, Pesut D, De Wit S, Gatell JM, Gazzard B, d'Arminio Monforte A, Rockstroh JK, Yazdanpanah Y, Champenois K, Jakobsen ML, Lundgren JD; HIDES Study Group.

PLoS One. 2019 Aug 13;14(8):e0220108. doi: 10.1371/journal.pone.0220108. eCollection 2019.

6.

The German National Registry of Primary Immunodeficiencies (2012-2017).

El-Helou SM, Biegner AK, Bode S, Ehl SR, Heeg M, Maccari ME, Ritterbusch H, Speckmann C, Rusch S, Scheible R, Warnatz K, Atschekzei F, Beider R, Ernst D, Gerschmann S, Jablonka A, Mielke G, Schmidt RE, Schürmann G, Sogkas G, Baumann UH, Klemann C, Viemann D, von Bernuth H, Krüger R, Hanitsch LG, Scheibenbogen CM, Wittke K, Albert MH, Eichinger A, Hauck F, Klein C, Rack-Hoch A, Sollinger FM, Avila A, Borte M, Borte S, Fasshauer M, Hauenherm A, Kellner N, Müller AH, Ülzen A, Bader P, Bakhtiar S, Lee JY, Heß U, Schubert R, Wölke S, Zielen S, Ghosh S, Laws HJ, Neubert J, Oommen PT, Hönig M, Schulz A, Steinmann S, Schwarz K, Dückers G, Lamers B, Langemeyer V, Niehues T, Shai S, Graf D, Müglich C, Schmalzing MT, Schwaneck EC, Tony HP, Dirks J, Haase G, Liese JG, Morbach H, Foell D, Hellige A, Wittkowski H, Masjosthusmann K, Mohr M, Geberzahn L, Hedrich CM, Müller C, Rösen-Wolff A, Roesler J, Zimmermann A, Behrends U, Rieber N, Schauer U, Handgretinger R, Holzer U, Henes J, Kanz L, Boesecke C, Rockstroh JK, Schwarze-Zander C, Wasmuth JC, Dilloo D, Hülsmann B, Schönberger S, Schreiber S, Zeuner R, Ankermann T, von Bismarck P, Huppertz HI, Kaiser-Labusch P, Greil J, Jakoby D, Kulozik AE, Metzler M, Naumann-Bartsch N, Sobik B, Graf N, Heine S, Kobbe R, Lehmberg K, Müller I, Herrmann F, Horneff G, Klein A, Peitz J, Schmidt N, Bielack S, Groß-Wieltsch U, Classen CF, Klasen J, Deutz P, Kamitz D, Lassay L, Tenbrock K, Wagner N, Bernbeck B, Brummel B, Lara-Villacanas E, Münstermann E, Schneider DT, Tietsch N, Westkemper M, Weiß M, Kramm C, Kühnle I, Kullmann S, Girschick H, Specker C, Vinnemeier-Laubenthal E, Haenicke H, Schulz C, Schweigerer L, Müller TG, Stiefel M, Belohradsky BH, Soetedjo V, Kindle G, Grimbacher B.

Front Immunol. 2019 Jul 19;10:1272. doi: 10.3389/fimmu.2019.01272. eCollection 2019.

7.

Too many people with viral hepatitis are diagnosed late - with dire consequences.

Lazarus JV, Picchio C, Dillon JF, Rockstroh JK, Weis N, Buti M.

Nat Rev Gastroenterol Hepatol. 2019 Aug;16(8):451-452. doi: 10.1038/s41575-019-0177-z. No abstract available.

PMID:
31320742
8.

Eliminating Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Berlin: A Modeling Analysis.

Martin NK, Jansen K, An der Heiden M, Boesecke C, Boyd A, Schewe K, Baumgarten A, Lutz T, Christensen S, Thielen A, Mauss S, Rockstroh JK, Skaathun B, Ingiliz P.

J Infect Dis. 2019 Oct 8;220(10):1635-1644. doi: 10.1093/infdis/jiz367.

PMID:
31301142
9.

Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART.

Dold L, Nielsen MJ, Praktiknjo M, Schwarze-Zander C, Boesecke C, Schierwagen R, Mohr R, Wasmuth JC, Jansen C, Bischoff J, Rockstroh JK, Karsdal MA, Spengler U, Trebicka J, Leeming DJ.

PLoS One. 2019 Jul 11;14(7):e0219526. doi: 10.1371/journal.pone.0219526. eCollection 2019.

10.

HepHIV2019 Bucharest Conference: challenges of timely and integrated testing and care.

Rockstroh JK, Simões D, Streinu-Cercel A.

Germs. 2019 Mar 1;9(1):8. doi: 10.18683/germs.2019.1151. eCollection 2019 Mar. No abstract available.

11.

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.

Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M.

AIDS. 2019 Jul 15;33(9):1455-1465. doi: 10.1097/QAD.0000000000002223.

12.

Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients.

Praktiknjo M, Djayadi N, Mohr R, Schierwagen R, Bischoff J, Dold L, Pohlmann A, Schwarze-Zander C, Wasmuth JC, Boesecke C, Rockstroh JK, Trebicka J.

Liver Int. 2019 Aug;39(8):1514-1520. doi: 10.1111/liv.14107. Epub 2019 Apr 5.

PMID:
30916873
13.

Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.

Bischoff J, Mauss S, Cordes C, Lutz T, Scholten S, Cornberg M, Manns MP, Baumgarten A, Rockstroh JK.

HIV Clin Trials. 2018 Dec;19(6):225-234. doi: 10.1080/15284336.2018.1538193.

PMID:
30890063
14.

Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany?

Bischoff J, Boesecke C, Ingiliz P, Berger F, Simon KG, Lutz T, Schewe CK, Schulze Zur Wiesch J, Hueppe D, Christensen S, Mauss S, Baumgarten A, Rockstroh JK; GECCO study group.

J Clin Gastroenterol. 2019 Feb 15. doi: 10.1097/MCG.0000000000001189. [Epub ahead of print]

PMID:
30789853
15.

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA.

Amele S, Peters L, Sluzhynska M, Yakovlev A, Scherrer A, Domingo P, Gerstoft J, Viard JP, Gisinger M, Flisiak R, Bhaghani S, Ristola M, Leen C, Jablonowska E, Wandeler G, Stellbrink H, Falconer K, D'Arminio Monforte A, Horban A, Rockstroh JK, Lundgren JD, Mocroft A; EuroSIDA study group.

HIV Med. 2019 Apr;20(4):264-273. doi: 10.1111/hiv.12711. Epub 2019 Feb 8.

PMID:
30734998
16.

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption.

Rockstroh JK, Asmuth D, Pantaleo G, Clotet B, Podzamczer D, van Lunzen J, Arastéh K, Mitsuyasu R, Peters B, Silvia N, Jolliffe D, Ökvist M, Krogsgaard K, Sommerfelt MA.

PLoS One. 2019 Jan 30;14(1):e0210965. doi: 10.1371/journal.pone.0210965. eCollection 2019.

17.

Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection.

Malin JJ, Boesecke C, Schwarze-Zander C, Wasmuth JC, Schlabe S, Trebicka J, Spengler U, Llibre JM, Jou T, Vasylyev M, Clotet B, Rockstroh JK.

HIV Med. 2019 Mar;20(3):230-236. doi: 10.1111/hiv.12705. Epub 2019 Jan 27.

PMID:
30687989
18.

Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men.

Popping S, Hullegie SJ, Boerekamps A, Rijnders BJA, de Knegt RJ, Rockstroh JK, Verbon A, Boucher CAB, Nichols BE, van de Vijver DAMC.

PLoS One. 2019 Jan 10;14(1):e0210179. doi: 10.1371/journal.pone.0210179. eCollection 2019.

19.

[Opportunistic infections: What's new?]

Boesecke C, Rockstroh JK, Thoden J.

Dtsch Med Wochenschr. 2018 Dec;143(24):1755-1758. doi: 10.1055/a-0641-9456. Epub 2018 Dec 3. German.

PMID:
30508854
20.

[Treatment of HIV in Pregnancy - Progress Over One Decade].

Pitzen IC, Otten LA, Dresbach T, Boesecke C, Wasmuth JC, Mueller A, Gembruch U, Merz WM, Strassburg CP, Haberl A, Rockstroh JK, Poralla S, Schwarze-Zander C.

Z Geburtshilfe Neonatol. 2019 Feb;223(1):26-32. doi: 10.1055/a-0741-7700. Epub 2018 Dec 4. German.

PMID:
30513543
21.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.

Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team.

Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Erratum in: Lancet. 2018 Nov 28;:.

PMID:
30420123
22.

Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial.

Dharan NJ, Neuhaus J, Rockstroh JK, Peters L, Gordin F, Arenas-Pinto A, Emerson C, Marks K, Hidalgo J, Sarmento-Castro R, Stephan C, Kumarasamy N, Emery S, Matthews GV; INSIGHT START Study Group.

Hepatology. 2019 Mar;69(3):1135-1150. doi: 10.1002/hep.30296. Epub 2019 Feb 19.

23.

Living donor liver transplant from an HIV-positive individual to an HIV-negative individual: could this become a new reality?

Rockstroh JK, González-Scarano F.

AIDS. 2018 Oct 23;32(16):2423-2424. doi: 10.1097/QAD.0000000000001999. No abstract available.

PMID:
30281559
24.

(Mid)West Side Story: Acute Hepatitis C Virus Infection and the Opioid Epidemic in the United States.

Boesecke C, Rockstroh JK.

Hepatology. 2019 Apr;69(4):1832-1834. doi: 10.1002/hep.30290. Epub 2019 Feb 20. No abstract available.

PMID:
30251386
25.

Are there any challenges left in hepatitis C virus therapy of HIV-infected patients?

Bischoff J, Rockstroh JK.

Int J Antimicrob Agents. 2018 Aug 23. pii: S0924-8579(18)30245-0. doi: 10.1016/j.ijantimicag.2018.08.019. [Epub ahead of print]

PMID:
30145247
26.

HIV testing history and access to treatment among migrants living with HIV in Europe.

Fakoya I, Álvarez-Del Arco D, Monge S, Copas AJ, Gennotte AF, Volny-Anne A, Wengenroth C, Touloumi G, Prins M, Barros H, Darling KE, Prestileo T, Del Amo J, Burns FM; aMASE Study Team.

J Int AIDS Soc. 2018 Jul;21 Suppl 4:e25123. doi: 10.1002/jia2.25123.

27.

The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations.

Lazarus JV, Safreed-Harmon K, Thursz MR, Dillon JF, El-Sayed MH, Elsharkawy AM, Hatzakis A, Jadoul M, Prestileo T, Razavi H, Rockstroh JK, Wiktor SZ, Colombo M.

Semin Liver Dis. 2018 Aug;38(3):181-192. doi: 10.1055/s-0038-1666841. Epub 2018 Jul 9. Review.

PMID:
29986353
28.

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.

Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, Rockstroh JK, Molina JM, Koenig E, Liu YP, Custodio J, Andreatta K, Graham H, Cheng A, Martin H, Quirk E.

Lancet HIV. 2018 Jul;5(7):e347-e356. doi: 10.1016/S2352-3018(18)30091-2. Epub 2018 Jun 18.

PMID:
29925490
29.

Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis.

Mohr R, Boesecke C, Dold L, Schierwagen R, Schwarze-Zander C, Wasmuth JC, Weisensee I, Rockstroh JK, Trebicka J.

Medicine (Baltimore). 2018 Apr;97(17):e0462. doi: 10.1097/MD.0000000000010462.

30.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C; DRIVE-FORWARD Study Group.

Lancet HIV. 2018 May;5(5):e211-e220. doi: 10.1016/S2352-3018(18)30021-3. Epub 2018 Mar 25.

PMID:
29592840
31.

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.

Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R, Bhagani S, Sherman KE, Shimonova T, Ruane P, Sasadeusz J, Slim J, Zhang Z, Samanta S, Ng TI, Gulati A, Kosloski MP, Shulman NS, Trinh R, Sulkowski M.

Clin Infect Dis. 2018 Sep 14;67(7):1010-1017. doi: 10.1093/cid/ciy220.

32.

High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.

von Felden J, Vermehren J, Ingiliz P, Mauss S, Lutz T, Simon KG, Busch HW, Baumgarten A, Schewe K, Hueppe D, Boesecke C, Rockstroh JK, Daeumer M, Luebke N, Timm J, Schulze Zur Wiesch J, Sarrazin C, Christensen S.

Aliment Pharmacol Ther. 2018 May;47(9):1288-1295. doi: 10.1111/apt.14592. Epub 2018 Mar 14.

PMID:
29536554
33.

Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0.

Ryom L, Boesecke C, Bracchi M, Ambrosioni J, Pozniak A, Arribas J, Behrens G, Mallon P, Puoti M, Rauch A, Miro JM, Kirk O, Marzolini C, Lundgren JD, Battegay M; EACS Governing Board.

HIV Med. 2018 May;19(5):309-315. doi: 10.1111/hiv.12600. Epub 2018 Mar 1.

34.

The HepHIV 2017 Conference in Malta: joining forces for the earlier diagnosis of HIV and viral hepatitis.

Raben D, Hoekstra M, Sperle I, Amato Gauci AJ, Gauci C, West B, Sullivan A, Lazarus JV, Platteau T, Rockstroh JK; HepHIV Conference Organising Committee and the HIV in Europe Steering Committee.

HIV Med. 2018 Feb;19 Suppl 1:5-10. doi: 10.1111/hiv.12588.

PMID:
29488707
35.

microRNA-200a: A stage-dependent biomarker and predictor of steatosis and liver cell injury in human immunodeficiency virus patients.

Austermann C, Schierwagen R, Mohr R, Anadol E, Klein S, Pohlmann A, Jansen C, Strassburg CP, Schwarze-Zander C, Boesecke C, Rockstroh JK, Odenthal M, Trebicka J.

Hepatol Commun. 2017 Feb 27;1(1):36-45. doi: 10.1002/hep4.1017. eCollection 2017 Feb.

36.

Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?

Bischoff J, Mauss S, Cordes C, Lutz T, Scholten S, Moll A, Jäger H, Cornberg M, Manns MP, Baumgarten A, Rockstroh JK.

HIV Med. 2018 Apr;19(4):299-307. doi: 10.1111/hiv.12579. Epub 2018 Jan 25.

PMID:
29368456
37.

Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients.

Anadol E, Lust K, Boesecke C, Schwarze-Zander C, Mohr R, Wasmuth JC, Rockstroh JK, Trebicka J.

PLoS One. 2018 Jan 18;13(1):e0191118. doi: 10.1371/journal.pone.0191118. eCollection 2018.

38.

Advances in the treatment of HIV/HCV coinfection in adults.

Schlabe S, Rockstroh JK.

Expert Opin Pharmacother. 2018 Jan;19(1):49-64. doi: 10.1080/14656566.2017.1419185. Review.

PMID:
29252031
39.

Is Hepatitis C Virus Elimination in Well-Defined Patient Groups Possible?

Rockstroh JK.

Clin Infect Dis. 2018 Apr 17;66(9):1366-1367. doi: 10.1093/cid/cix1010. No abstract available.

PMID:
29186326
40.

Massive Paraesophageal Varices in the Absence of Liver Cirrhosis.

Boesecke C, Rockstroh JK, Wasmuth JC.

Dtsch Arztebl Int. 2017 Oct 13;114(41):701. doi: 10.3238/arztebl.2017.0701. No abstract available.

41.

Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection.

Boesecke C, Ingiliz P, Berger F, Lutz T, Schewe K, Schulze Zur Wiesch J, Baumgarten A, Christensen S, Rockstroh JK, Mauss S; GECCO Study Group.

Open Forum Infect Dis. 2017 Jul 27;4(3):ofx158. doi: 10.1093/ofid/ofx158. eCollection 2017 Summer.

42.

Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.

Rockstroh JK, Orkin C, Viani RM, Wyles D, Luetkemeyer AF, Lazzarin A, Soto-Malave R, Nelson MR, Bhagani SR, Klinker HHF, Rizzardini G, Girard PM, Tural C, Shulman NS, Mobashery N, Hu YB, Fredrick LM, Pilot-Matias T, Trinh R, Gane E.

Open Forum Infect Dis. 2017 Jul 22;4(3):ofx154. doi: 10.1093/ofid/ofx154. eCollection 2017 Summer.

43.

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

Cahn P, Kaplan R, Sax PE, Squires K, Molina JM, Avihingsanon A, Ratanasuwan W, Rojas E, Rassool M, Bloch M, Vandekerckhove L, Ruane P, Yazdanpanah Y, Katlama C, Xu X, Rodgers A, East L, Wenning L, Rawlins S, Homony B, Sklar P, Nguyen BY, Leavitt R, Teppler H; ONCEMRK Study Group.

Lancet HIV. 2017 Nov;4(11):e486-e494. doi: 10.1016/S2352-3018(17)30128-5. Epub 2017 Sep 11.

PMID:
28918877
44.

Moderate endurance training (marathon-training) - effects on immunologic and metabolic parameters in HIV-infected patients: the 42 KM cologne project.

Schlabe S, Vogel M, Boesecke C, Schwarze-Zander C, Rockstroh JK, Körner C, Brixius K, Wasmuth JC.

BMC Infect Dis. 2017 Aug 8;17(1):550. doi: 10.1186/s12879-017-2651-y.

45.

Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?

Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB.

J Int AIDS Soc. 2017 Jul 28;20(1):22146. doi: 10.7448/IAS.20.1.22146.

46.

Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.

Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Alberto Arnaiz J, Cooper D, Rockstroh JK, Mallon P, Emery S; MARCH study group.

HIV Med. 2018 Jan;19(1):65-71. doi: 10.1111/hiv.12532. Epub 2017 Jul 13.

PMID:
28703491
47.

[HCV healing also in HIV infected patients].

Rockstroh JK.

MMW Fortschr Med. 2017 Jun;159(Suppl 2):56-60. doi: 10.1007/s15006-017-9739-6. Review. German. No abstract available.

PMID:
28597261
48.

Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women.

Schalkwijk S, Colbers A, Konopnicki D, Gingelmaier A, Lambert J, van der Ende M, Moltó J, Burger D; Pharmacokinetics of newly developed antiretroviral agents in HIV-infected pregnant women (PANNA) Network.

Clin Infect Dis. 2017 Oct 15;65(8):1335-1341. doi: 10.1093/cid/cix534.

PMID:
28595298
49.

Genetic polymorphisms associated with fatty liver disease and fibrosis in HIV positive patients receiving combined antiretroviral therapy (cART).

Dold L, Luda C, Schwarze-Zander C, Boesecke C, Hansel C, Nischalke HD, Lutz P, Mohr R, Wasmuth JC, Strassburg CP, Trebicka J, Rockstroh JK, Spengler U.

PLoS One. 2017 Jun 8;12(6):e0178685. doi: 10.1371/journal.pone.0178685. eCollection 2017.

50.

Compartment-specific distribution of human intestinal innate lymphoid cells is altered in HIV patients under effective therapy.

Krämer B, Goeser F, Lutz P, Glässner A, Boesecke C, Schwarze-Zander C, Kaczmarek D, Nischalke HD, Branchi V, Manekeller S, Hüneburg R, van Bremen T, Weismüller T, Strassburg CP, Rockstroh JK, Spengler U, Nattermann J.

PLoS Pathog. 2017 May 15;13(5):e1006373. doi: 10.1371/journal.ppat.1006373. eCollection 2017 May.

Supplemental Content

Loading ...
Support Center